

Spring To Life

Spring to Life Conference on Hematologic Malignancies, a CE-accredited, multisponsored, one-day educational conference

Saturday, May 3, 2014

Registration, Breakfast, Exhibits – 7:30AM–8:00AM

Healthcare Professional Program – 7:30AM–1:00PM

Lunch, Networking, Exhibits – 12:00PM–1:00PM

Patient-Centered Program – 1:00PM–4:15PM

Desmond Hotel

660 Albany Shaker Road

Albany, NY 12211

Partners and Accredited Providers



CME
program



NEW YORK ONCOLOGY HEMATOLOGY, P.C.



LEUKEMIA &
LYMPHOMA
SOCIETY™


fighting blood cancers



BE  THE MATCH®



PHARMCON
Continuing Education For Healthcare Professionals
freeCE.COM



Spring To Life

Presentation Download

Program presentations
will be posted online within 30 days at:

www.Spring2LifeHeme.org

Click on *2014 Slide Presentations*


Enter Program Code: S2L14



Internet Access

Connect to *The Desmond* network.

Open browser and accept the terms on the default landing page.



Dear Healthcare Professional Colleagues:

Welcome to the inaugural ***Spring to Life Conference on Hematologic Malignancies!*** We are so pleased that you have chosen to attend, learn, engage, and earn CE credits.

This annual conference has a twofold mission. In the morning session, we focus on updating the state of the art in the science, medicine, research, and emerging therapies of hematologic malignancies. Then, in an interactive afternoon session that is open to the broader general community, we dedicate our focus to the varied issues and impacts of these diseases in the lives of our patients, families, and communities, encompassing the emotional, psychological, social, and spiritual dimensions of our human experience. Please feel free to share in the afternoon program, as your time permits.

This year we focus on ***The Acute Leukemias***—AML and ALL. We have a collaboration of presenters from NYOH and the Dana-Farber Cancer Institute and, given the pediatric dimension of the acute leukemias, we have incorporated the childhood perspective via collaboration with The Melodies Center for Childhood Cancers and Blood Disorders at Albany Medical Center.


Please also take note of our grantors and exhibitors for this meeting, whose generosity and support is integral to making this conference a reality for our region.

On behalf of our Organizing Committee, thank you again for attending; please learn and enjoy!

Sincerely,

Ira Zackon, MD, Program Chair

New York Oncology Hematology, PC



Agenda

Healthcare Professional Program

7:30AM–8:00AM	Registration, Breakfast, Exhibits
8:00AM–10:20AM	Session 1 <ul style="list-style-type: none">■ <i>Opening remarks (5 min)</i> Ira Zackon, NYOH, Albany, NY■ <i>What's old: Childhood ALL: Paradigms of curative therapy (30 min)</i> Vikramjit Kanwar, Albany Medical College, Albany, NY■ <i>What's new: The emerging science of AML (35 min)</i> R Coleman Lindsley, Dana-Farber Cancer Institute, Boston, MA■ <i>Current management of adult AML (35 min)</i> Sami Brake, NYOH, Albany, NY■ <i>Allogeneic bone marrow stem cell transplantation (35 min)</i> Robert Soiffer, Dana-Farber Cancer Institute, Boston, MA
10:20AM–10:35AM	Break, Snacks, and Exhibits
10:35AM–12:00PM	Session 2 <ul style="list-style-type: none">■ <i>Translational research and emerging therapies (35 min)</i> Courtney Bellomo, NYOH, Albany, NY■ <i>Keynote Address: Acute promyelocytic leukemia (APL): Cure without chemotherapy? (50 min)</i> Daniel DeAngelo, Dana-Farber Cancer Institute, Boston, MA
12:00PM	Lunch, Networking, Exhibits

Patient-Centered Program

1:00PM–2:00PM	Session 1 <i>Patient experiences and interactive panel discussions</i> <ul style="list-style-type: none">■ <i>Rhythms of therapy, dysrhythms of life</i>■ <i>Coming together: How families and relationships survive cancer</i>
2:00PM–2:15PM	Break, Snacks, and Exhibits
2:15PM–4:15PM	Session 2 <i>Patient experiences and interactive panel discussions</i> <ul style="list-style-type: none">■ <i>Unique issues of life for bone marrow transplant patients</i>■ <i>Being a cancer survivor</i>■ <i>Transitions: What now? When treatment ends</i>■ <i>Inspirational Speaker: Humor, hearts, and hope</i>
4:10PM–4:15PM	Concluding Remarks <ul style="list-style-type: none">■ <i>Look ahead to next year</i>

Program Description

The **Spring to Life Conference on Hematologic Malignancies: Acute Leukemia** is an accredited, multisponsored, one-day, educational program developed by New York Oncology Hematology (NYOH), in collaboration with Medical College of Wisconsin (MCW), the Leukemia & Lymphoma Society® (LLS), the National Marrow Donor Program (NMDP), Be The Match®, PharmCon, and a panel of expert faculty from the academic, research, and community practice settings.

The 2014 Spring to Life program will focus on multidisciplinary care for patients with an acute leukemia. Specifically, clinician sessions will detail evidence-based treatment standards for acute leukemias, optimal use of multimodality treatments, current controversies in the field, and ongoing translational and clinical studies. The conference will partner national experts, community practitioners,

Learning Objectives

Upon completion of this symposium, healthcare professionals will be better able to:

- Apply the knowledge gained regarding the science and clinical management of acute leukemias to improve patient care
- Critically evaluate and integrate emerging data related to acute leukemias
- Discuss what is known about the effectiveness of therapies for the acute leukemias, including the appropriate role and timing of hematopoietic stem cell transplantation
- Apply strategies to enhance coordination of care for patients with acute leukemias
- Communicate the benefits and harms of each medical option to your patients with an acute leukemia, and their families/caregivers, while engaging in shared decision making
- Collaborate in and optimize holistic supportive care through enhanced understanding of the leukemia experience on patients, families, and caregivers (primary care and ancillary health care providers)

Target Audience

The target audience for this conference is family and primary care practitioners, hematologists, oncologists, pediatricians, allied health professionals (including nurses, pharmacists, and social workers), basic scientists, and members of the community (including patients and their family and caregivers).


and members of the community in order to enhance understanding and collaboration between these groups, and to foster better care for and communication with patients with hematologic malignancies.

With programming both for healthcare professionals and the community, the goal of this activity is to bring together cancer care providers and members of the community—including patients, survivors, and their family and caregivers—to gain an up-to-date understanding of blood cancers, including the state-of-the-art science behind them, their clinical management, ongoing translational research, and emerging therapies. The program will also provide perspectives on the impact cancer has on the lives of patients and families.

Healthcare professionals are welcome and encouraged to participate in the afternoon patient-centered sessions.

Fee Information

There is no fee for this educational activity.



Accreditation Statements

LLS Nursing Accreditation Statement

Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Professional number CEP 5832 to award 4.0 continuing education contact hours through the California Board of Registered Nursing.

LLS Social Worker Accreditation Statement

The Leukemia & Lymphoma Society (LLS), Professional number 1105, is approved as a Professional for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org Approved Continuing Education Program (ACE). Approval Period: December 2011-December 2014. LLS maintains responsibility for the program. Social workers should contact their regulatory board to determine course approval. Social workers will receive 4.0 CE clock hours.

PharmCon, Inc.



PharmCon, Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a Professional of continuing pharmacy education.

PharmCon will provide a maximum of 4.0 hours of continuing education credits.

ACCME Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and New York Oncology Hematology. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement

The Medical College of Wisconsin designates this live activity for a maximum of 4.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Medical College of Wisconsin designates this activity for a maximum of 4.0 hours of participation for continuing education for allied health professionals.



CME
program



Faculty

Courtney Bellomo, MD

Hematologist/Oncologist, NYOH, PC
Clinical Assistant Professor, Albany Medical College
Albany, NY

Sami Brake, MD

Hematologist/Oncologist, NYOH, PC
Clinical Assistant Professor, Albany Medical College
Albany, NY

Daniel J DeAngelo, MD, PhD

Physician, Dana-Farber Cancer Institute
Associate Professor, Harvard Medical School
Boston, MA

Vikramjit S Kanwar, MRCP (UK), MBA, FAAP

Chief, Division of Pediatric Hematology Oncology
Director, Melodies Center for Childhood Cancer and Blood Disorders
Professor, Department of Pediatrics
Albany Medical Center
Albany, NY

R Coleman Lindsley, MD, PhD

Physician, Dana-Farber Cancer Institute
Instructor of Medicine, Harvard Medical School
Boston, MA

Robert Soiffer, MD

Chief, Division of Hematologic Malignancies
Co-Chief, Stem Cell Transplant Program
Dana-Farber Cancer Institute
Professor, Harvard Medical School
Boston, MA

Ira Zackon, MD (Chair)

Hematologist/Oncologist
Director, Stem Cell Transplant
NYOH, PC
Albany, NY

Planning Committee

Courtney Bellomo, MD

Hematologist/Oncologist, NYOH, PC
Clinical Assistant Professor, Albany Medical College
Albany, NY

Vikramjit S Kanwar, MRCP (UK), MBA, FAAP


Chief, Division of Pediatric Hematology Oncology
Director, Melodies Center for Childhood Cancer and Blood Disorders
Professor, Department of Pediatrics
Albany Medical Center
Albany, NY

Ira Zackon, MD (Chair)

Hematologist/Oncologist
Director, Stem Cell Transplant
NYOH, PC
Albany, NY

Disclosure of Conflict of Interest

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.



Faculty Biographies


Courtney Bellomo, MD, is a hematologist/oncologist and stem cell transplant physician at New York Oncology Hematology, PC (NYOH) and clinical assistant professor at Albany Medical College in Albany, New York. After earning a medical degree in 2006 from Robert Wood Johnson Medical School in Piscataway, New Jersey, she completed an internal medicine residency and a hematology/oncology fellowship at Robert Wood Johnson University Hospital in New Brunswick, New Jersey. In 2009, she served as chief resident of the internal medicine residency program. She joined the staff at NYOH in June 2013.

Sami Brake, MD, is a hematologist/oncologist at New York Oncology Hematology, PC (NYOH) in Albany, New York. After earning a medical degree in 2004 from Damascus University School of Medicine in Damascus, Syria, Dr. Brake completed a residency in internal medicine and a fellowship in hematology/oncology at the Henry Ford Health System in Detroit, Michigan. In 2011, he joined the staff at NYOH.

Daniel DeAngelo, MD, PhD, is an associate professor of medicine at Harvard Medical School and a senior physician within the adult leukemia program at Dana-Farber Cancer Institute (DFCI) in Boston, Massachusetts. In 1993, he earned an MD and a PhD from Albert Einstein College of Medicine in Bronx, New York. He completed a residency in internal medicine at Massachusetts General Hospital in Boston in 1996. Upon completing clinical fellowships in medicine and hematology-oncology at Brigham and Women's Hospital and Dana-Farber/Partners Cancer

Care, respectively, in 1999, Dr. DeAngelo joined the faculty at Harvard Medical School. During his clinical fellowship, he also completed a postdoctoral research fellowship in the laboratory of Dr. Bruce Spigelman at DFCI. Dr. DeAngelo is responsible for clinical trial development for patients with acute and chronic leukemias, myelodysplastic syndromes, and myeloproliferative disorders. His research interests revolve around the use of novel therapeutics specifically phase I therapies for the treatment of hematologic disorders.

Vikramjit Kanwar, MD, MRCP (UK), MBA, is chief of the division of pediatric hematology oncology, director of the Melodies Center for Childhood Cancer and Blood Disorders, and professor of pediatrics at Albany Medical College in Albany, New York. After earning his MBBS from All India Institute of Medical Sciences in New Delhi, India in 1986, he became a Member of Royal College of Physicians, UK in pediatrics in 1989 and completed a pediatric residency at University of California Irvine (UCI) Medical Center in Orange, California in 1993. In 1996 he completed a fellowship in pediatric hematology/oncology at St. Jude Children's Research Hospital in Memphis, Tennessee. He spent over 5 years as an attending physician in pediatrics in Western New York, during which time he also earned an MBA from the William E Simon Graduate School in Rochester, New York. In 2003 he became an attending physician in pediatric hematology-oncology at Legacy Emanuel Children's Hospital in Portland, Oregon and from 2005 he has




been at Albany Medical Center. Dr. Kanwar is the principal investigator for the Children's Oncology Group (COG) for Albany Medical Center and oversees all COG research protocols at the institution, as well as serving on the national COG Executive Committee. He specializes in diagnosing and treating infants, children and adolescents with a wide range of childhood cancers such as leukemia, lymphoma, brain tumors, germ cell tumors, and neuroblastoma.

R Coleman Lindsley, MD, PhD, is an instructor in medicine at Harvard Medical School and associate physician at Brigham and Women's Hospital in Boston, Massachusetts. After earning an MD and PhD from Washington University School of Medicine in St. Louis, Missouri in 2008, he completed an internal medicine residency at Brigham and Women's Hospital in 2010 and a hematology/oncology fellowship at Dana-Farber/Partners Cancer Care in 2013 in Boston. In 2013, Dr. Lindsley joined the faculty at Harvard Medical School. His primary research interest is the biology and genetics of myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia.

Robert Soiffer, MD, is professor of medicine at Harvard Medical School and chief of the division of hematologic malignancies. He is also co-director of the bone marrow transplant service at Dana-Farber Cancer Institute (DFCI) in Boston, Massachusetts. After earning a medical degree from the New York University School of Medicine in 1983 in New York, New York, Dr. Soiffer completed a residency in internal medicine at Brigham and Women's Hospital in Boston, where he also served as chief medical resident. He completed a fellowship in medical oncology at

DFCI in 1988, before joining the faculty at Harvard Medical School the same year. Dr. Soiffer's research focuses on modulation of immune responses in the setting of hematopoietic stem cell transplantation. The ultimate goal for his clinical trials and research grants is to optimize graft-versus-leukemia activity without inducing graft-versus-host disease.

Ira Zackon, MD, is a hematologist/oncologist and director of the stem cell transplant program at New York Oncology Hematology, PC (NYOH) and assistant clinical professor at Albany Medical College in Albany, New York. After earning a medical degree in 1986 from McGill University in Montreal, Quebec, Canada, he completed an internship and residency in medicine at Royal Victoria Hospital in Montreal in 1987. Dr. Zackon completed fellowships in hematology/oncology at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire (1990-1992) and Northwestern University Medical Center, Chicago, Illinois (1992-1994). At NYOH, Dr. Zackon has developed the practice's autologous stem cell transplant program, expanded collaborative care for allogeneic bone marrow transplant patients at NYOH with regional transplant centers, and focused NYOH participation in research trials in the hematologic malignancies through the US Oncology network and the Blood Cancer Research Partnership in association with the Dana-Farber Cancer Institute in Boston, Massachusetts.



Faculty Disclosures

The following program speakers have no relevant financial relationships to disclose:

Courtney Bellomo, MD

Sami Brake, MD

Daniel DeAngelo, MD, PhD

R Coleman Lindsley, MD, PhD

The following speakers have relevant financial relationships to disclose:

Vikramjit Kanwar, MRCP (UK), MBA, FAAP

*Advisory Board and Speakers' Bureau:
Jazz Pharmaceuticals*

Robert Soiffer, MD

*Consultant: Takeda Pharmaceutical Company Limited, GlaxoSmithKline; Research Support:
Fresenius*

Ira Zackon, MD

Speakers' Bureau: Millenium Pharmaceuticals

Planner Disclosures

The following staff and program planners have no relevant financial relationships to disclose:

Courtney Bellomo, MD, Hematology/Oncology,
NYOH, PC, Albany, NY

Kim Farina, PhD, Principal and Medical Writer,
BenComm Health and Medical Communications,
Houston, TX

Linda Pulver, Director, Clinical Services, NYOH, PC,
Albany, NY


The following staff and program planners have relevant financial relationships to disclose:

Vikramjit Kanwar, MRCP (UK), MBA, FAAP

*Advisory Board and Speakers' Bureau:
Jazz Pharmaceuticals*

Ira Zackon, MD

Speakers' Bureau: Millenium Pharmaceuticals



The **First Annual Spring to Life Conference on Hematologic Malignancies** is supported by unrestricted educational grants provided by the following:



Jazz Pharmaceuticals plc




LLS grant provided by unrestricted educational grants from:



Thank you to the following exhibitors for supporting this program:





NEW YORK ONCOLOGY HEMATOLOGY, P.C.

This activity is jointly provided by the Medical College of Wisconsin and New York Oncology Hematology, PC.